OPRX Stock: $102 Price Target From B. Riley

By Amit Chowdhry ● Oct 19, 2021
  • The shares of OptimizeRx Corporation (NASDAQ: OPRX) have received a price target of $102 from B. Riley. These are the details.

The shares of OptimizeRx Corporation (NASDAQ: OPRX) have received a price target of $102 from B. Riley. And B. Riley analyst Marc Wiesenberger had resumed coverage of OptimizeRx with a “Buy” rating.

Wiesenberger noted that the pandemic exposed longstanding inefficiencies within operating models at pharmaceutical companies, which created a tipping point for overdue transformation. And Wiesenberger pointed out that OptimizeRx’s proprietary and highly scalable electronic health communications network supports improved patient outcomes through treatment access and adherence tools along with offering digital tools for life science companies to differentiate and modernize the go-to-market strategies targeted at physicians.

OptimizeRx connects over 60% of U.S. healthcare providers and millions of their patients through a proprietary point-of-care network. And the connectivity is facilitated via its integrated Therapy Initiation and Persistence Platform.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.